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Abstract
Background: Obesity is a modifiable risk factor for hypertension and T2D. 
Objective(s): We examined relations between fasting plasma adiponectin (ADIP), C-reactive protein (CRP) concentrations and 
markers of  T2D in African Americans (AA). 
Methods: Fasting plasma ADIP, CRP, Insulin (IN), HOMA-IR, lipid profiles, body fat percent (%BF), waist circumference 
(WC), body mass index (BMI) and blood pressure measures were determined in AA women (W: n=77) and men (M: n=34). Par-
ticipants were classified into: 1) Normal fasting glucose (FG) and Normal %BF; 2) Normal FG and High %BF; and 3) High FG. 
Results: Compared to men, women had significantly higher mean ADIP (W: 31.4±2.9 vs. M: 18.0±4.4 ng/L), CRP (W: 3.2±0.3 
vs. M: 2.0±0.5 mg/L), %BF (W: 41.2±0.9 vs. M: 27.2±1.3), and BMI (W: 32.3±0.7 vs. M: 29.2±1.1 kg/m2). Women with normal 
FG and %BF had significantly higher ADIP (64.0±6.0) and lower CRP (1.3±0.6) concentrations than normal FG/ high %BF 
(ADIP: 37.0±5.0 and CRP: 3.1    0.5) and high FG (ADIP: 15.1±4.1 and CRP: 4.0     0.5) groups. Women with high ADIP to 
CRP ratio had favorable metabolic and anthropometric profiles. 
Conclusion: Low ADIP and high CRP are associated with excessive %BF and FG in AA women. ADIP/CRP, may be useful 
for detecting metabolic dysregulation.
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Obesity, defined as an accumulation of  excess body fat1,2, 
increases the risk of  developing insulin resistance (IR) 
and type 2 diabetes (T2D)3. Since these conditions reflect 
metabolic dysregulation and likely systemic inflamma-
tion, interest in various bio-active proteins has emerged. 
Two proteins of  interest are adiponectin and C reactive 
protein (CRP), produced by adipose tissue and the liver, 
respectively4. The significant inverse correlation between 
anti-inflammatory adiponectin and pro-inflammatory 
CRP reported in certain obese, diabetic and coronary ar-
tery disease (CAD) populations5, underscores the impor-
tance of  investigating adiponectin and CRP together to 
elucidate their opposing relationships in obesity and T2D. 
Adipose tissue has traditionally been seen as a storage 
place for fatty acids; however this notion has been re-
placed over the last years and adipose tissue has been rec-
ognized to play a central role in lipid and glucose metabo-
lism and production of  various hormones and cytokines6. 
Adipose tissue is an active endocrine organ that secretes 
adipocytokines, such as adiponectin.  Adiponectin has 
anti-diabetic and anti-inflammatory properties7 and ap-
pears to be higher in women than men8-10. Discovered in 
the mid-1990s by four different research groups, it is also 
referred to as Acrp30, AdipoQ, ApM1, and GBP2811. 
Within the general population, high adiponectin levels 
± ±
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have been associated with positive cardiovascular bene-
fits; whereas low values of  adiponectin have been linked 
to a variety of  health risks - obesity, metabolic syndrome 
(MS), IR, T2D and unfavorable lipid profiles12-15. Other 
studies have reported that individuals with CAD and/or 
T2D have lower plasma adiponectin levels than age- and 
body mass index- (BMI) matched, non-diabetic individu-
als without CAD16. Little is known about the regulation 
of  adiponectin, especially in African Americans (AA) and 
most of  the factors and mechanisms affecting adiponec-
tin levels are poorly described17. 
CRP is another important systemic marker for inflamma-
tion and high CRP levels have also been linked to multiple 
health risks - obesity, T2D, cardiovascular disease (CVD), 
and hyperlipidemia18-20. Due to the apparent strong as-
sociations between CRP and health risks, the American 
Heart Association and Centers for Disease Control and 
Prevention evaluated CRP as a risk assessment tool and 
proposed cut points of  <1 mg/L, 1-3 mg/L and >3 mg/L 
be used to identify those at low, average, and high relative 
risk, respectively for CVD21. Plasma CRP correlates posi-
tively with body fat mass, visceral adipose tissue accumu-
lation and plasma insulin22, and is associated with T2D23. 
Conflicting results have been found with regard to gender 
differences in CRP. Whereas some studies have reported 
higher CRP levels in women24,25, others have found no 
gender differences26. Ethnic differences in CRP concen-
trations have also been noted: two large cohort studies 
found that CRP tends to be higher in AA and Hispanic 
women than Caucasians and Asian women27,28.
However, some obese individuals are free from obesity-re-
lated metabolic complications29. The aim of  this study 
was to evaluate  associated patterns of  plasma adiponec-
tin and high sensitivity CRP (hs-CRP) concentrations as a 
function of  metabolic risk factors  - fasting blood glucose 
(FG), insulin (IN), waist circumference (WC), percent 
body fat (% BF), mean arterial blood pressure (MAP) 
and plasma lipids (high density lipoprotein cholesterol/
HDL-C and triglycerides/TG). We hypothesized that, 
among individuals with increased FG and %BF, combin-
ing adiponectin and CRP would provide a valuable index 
of  obesity related inflammatory and metabolic markers. 
Therefore, we examined mean differences in metabolic 
characteristics based on the combined measurements of  
adiponectin and CRP in AA men and women after clas-
sifying participants into three metabolic risk groups: (a) 
normal FG and %BF; (b) normal FG and high %BF; and 
(c) high FG. In addition we determined whether the plas-
ma adiponectin to CRP ratio level would be a predictive 
measure of  metabolic risk.  
Methods
Study population
Participants with complete dataset included 111 AA men 
(n= 34) and women (n = 77) between 18 to 60 years of  age 
who were recruited between January 2008 and September 
2009 through public advertisements and announcements 
at local churches in the Greater Washington DC area. 
Participants who were pregnant or taking steroid medi-
cations were excluded for distinct hormonal profiles as-
sociated with circulating levels of  adiponectin. The study 
was approved by the Institutional Review Board of  the 
Uniformed Services University of  the Health Sciences 
(USUHS), and written informed consent was obtained 
from all participants. 
Procedures
Participants visited the laboratory between 0700 and 0900 
AM, wherein after obtaining informed consent, blood 
pressure (BP) and anthropometric evaluations were ob-
tained. Baseline blood collections were obtained after 
an overnight fast for determination of  glucose, insulin, 
HDL-C, TG, hs-CRP and adiponectin.
Anthropometric measurements
Body weight was measured with a calibrated balance beam 
metric scale to the nearest 0.1kg and height was measured 
with a stadiometer to the nearest 0.1cm. BMI was calcu-
lated from height and weight (kg/m2). %BF was estimat-
ed by using bioelectric impedance and calculated with the 
NHANES III prediction formula. WC was measured at 
the midpoint between the lower rib margin and the iliac 
crest by using a non-elastic measuring tape. Baseline BP 
was recorded with a standard BP monitor: measurements 
were obtained on at least two occasions with the partic-
ipant in a seated position to ensure accurate assessment. 
Mean arterial pressure (MAP) was calculated using the 
formula ((2*Diastolic BP) + (Systolic BP))/330. 
Physiological and biochemical measurements
Fasting blood glucose concentration was measured with 
One Touch Ultra monitoring system,  hs-CRP analyses 
were carried out with an Immulite 2000 analyzer (Siemens 
Medical Solutions Diagnostics, Erlanger, Germany), Insu-
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lin was detected using the Human Insulin ELISA kit from 
Millipore (St.Charles, Missouri, USA),  Adiponectin was 
detected using the Human Adiponectin  sandwich immu-
noassay kit from Meso Scale Discovery (Gaithersburg, 
MD, USA) and lipid profiles (Total Cholesterol, HDL-C, 
LDL-C and TG) were determined in the Clinical Labora-
tory at the National Institutes of  Health Department of  
Laboratory Medicine using an LX-20 analyzer (Beckman, 
San Diego, CA). Mean values are expressed in mm/L, 
µU/mL, mg/L, ng/mL and mmol/L respectively. Insu-
lin Resistance was defined by using homeostasis model 
asessment method of  insulin resistance (HOMA-IR) 
(glucose [in millimoles per liter] x insulin [in microunits 
per milliliter]/22.5).
Statistical analysis
The frequency and distributions of  variables were exam-
ined to determine normality of  distribution and identify 
outliers. Distributions of  plasma adiponectin and CRP 
levels were skewed, so natural log transformed values 
were used to normalize the variables for analyses. Men 
and women with a %BF ≥ 25.1 and 35.1 respectively, 
were categorized as high %BF and participants with FG 
≥ 6.1 mmL were considered as diabetic. Three groups 
were then formed based on FG and %BF: 1) low risk – 
normal FG and %BF; 2) moderate risk – normal FG and 
high %BF; and 3) high risk - high FG. Covariates, such as 
age and income, were controlled for in all analyses. 
In addition, the ratio of  adiponectin (values were multi-
plied by 1,000 to generate whole numbers greater than 
0.1) to CRP was calculated (mg/L). Cut points were made 
for 2 groups and participants in the lower point of  adi-
ponectin to CRP ratio were classified as “high risk”, par-
ticipants in the upper point were classified as “low risk”.
Multivariate analyses of  variance (MANOVA) were used 
to determine differences in (1) metabolic (FG, IN, HO-
MA-IR), lipid profiles (TC, TG, LDL-C and HDL-C) and 
physical variables (BMI, %BF, WC, MAP) as a function 
of  metabolic grouping low and high adiponectin to CRP 
ratio and (2) variations in plasma adiponectin, CRP and 
adiponectin to CRP ratio in the three %BF and diabetes 
status groups. Partial correlations were calculated to find 
associations between adiponectin and CRP with physical, 
lipid and metabolic measurements. 
The sample size of  111 (69% female) was adequate to de-
tect moderate group differences across two independent 
groups of  different sizes (d=0.6), and across three sized 
groups (f=0.30). Participants with complete data were in-
cluded in the present analysis. Results are expressed as 
mean ± SEM and the statistical significance was set at p ≤ 
0.05. Statistical analyses were performed with IBM SPSS 
20.0 for Windows (SPSS Inc., Chicago, Ill., USA). 
Results 
Compared to men, women had higher plasma hs-CRP 
(Women: 3.2 ± 0.3 mg/L, Men: 2.0 ± 0.5 mg/L; p ≤ 
0.05), adiponectin (Women: 31.4 ± 2.9 ng/mL, Men: 18.0 
± 4.4 ng/mL; p ≤ 0.05), %BF (Women: 41.2 ± 0.9, Men: 
27.2 ± 1.3; p ≤ 0.001) and BMI (Women: 32.3 ± 0.7, 
Table 1: Metabolic and physical characteristics by gender (Mean ± S.E.M) 
  
Note: Mean Differences significant at *p≤ 0.05, **p ≤0.01, ***p≤0.001 (controlled for age and income;1ratio of 
adiponectin (values multiplied by 1000 to generate whole numbers) to CRP. 
Abbreviations: C reactive protein (CRP); Low-Density Lipoprotein Cholesterol (LDL-C); High-Density Lipoprotein 




Variables Women (n=77) Men (n=34) 
CRP (mg/L)* 3.2 ± 0.3 2.0 ± 0.5 
Adiponectin (ng/mL)** 31.4 ± 2.9 18.0 ± 4.4 
1Adiponectin/CRP ratio 43.2 ± 7.5 28.0 ± 11.3 
Total Cholesterol (mmol/L) 4.1 ± 0.1 4.0 ± 0.1 
Triglycerides (mmol/L) 1.0 ± 0.1 1.2 ± 0.1 
LDL-C (mmol/L) 2.4 ± 0.1 2.3 ± 0.1 
HDL-C (mmol/L) 1.3 ± 0.04 1.2 ± 0.06 
Fasting Glucose (mmol/L) 6.2 ± 0.2 6.3 ± 0.2 
Insulin (µU/mL) 7.5 ± 0.9 7.4 ± 1.3 
HOMA-IR 2.2 ± 0.3 2.2 ± 0.4 
Waist Circumference (cm) 99.0 ± 2.0 98.5 ± 3.0 
Percent Body Fat*** 41.2 ± 0.9 27.2 ± 1.3 
Body Mass Index (kg/m2)* 32.3 ± 0.7 29.2 ± 1.1 
MAP (mm Hg) 99.0 ± 2.0 101.0 ± 2.3 
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IN and HOMA-IR, in women only.
Table 3 shows metabolic and physical baseline differenc-
es based on low and high adiponectin to CRP ratio. AA 
women with a high adiponectin to CRP ratio had signifi-
cantly lower FG, IN, HOMA-IR, WC, %BF and BMI 
while for men, only HDL-C, BMI and %BF were signifi-
Men: 29.2 ± 1.1; p ≤ 0.05), as shown in Table 1.  
Table 2 presents correlation coefficients for plasma ad-
iponectin and CRP with physical (BMI, WC, MAP and 
%BF), metabolic and lipid (FG, IN, HOMA-IR, TC, TG, 
LDL-C and HDL-C) variables. A significant negative cor-
relation was observed between plasma adiponectin and 
CRP in AA men (r = -0.39, p ≤ 0.05) and women (r = 
-0.32, p ≤ 0.01). Adiponectin was significantly and neg-
atively associated with BMI and WC in both men and 
women, whereas in women only, adiponectin was also 
associated with %BF, IN, FG and HOMA-IR.  In men, 
there was a significant negative association between CRP 
and HDL-C; a positive association between CRP and 
BMI in both men and women and with WC, %BF, FG, 
Table 2: Partial correlations between adiponectin, CRP, physical and 
metabolic variables by gender (Women: n = 77; Men: n = 34) 
 
Variables Adiponectin CRP 
  Women Men Women Men 
Adiponectin (mg/L) - - -0.32** -0.34* 
CRP (mg/L) -0.32** -0.39* - - 
BMI (kg/m2) -0.23* -0.40* 0.51*** 0.45** 
WC (cm) -0.30** -0.34* 0.57*** 0.32 
MAP (mm Hg) 0.13 -0.13 0.16 0.002 
Body Fat (%) -0.24* -0.26 0.50*** 0.33 
FG (mmol/L) -0.34** -0.05 0.30** -0.10 
IN (µU/mL) -0.33** -0.11 0.30* 0.17 
HOMA-IR -0.33** -0.12 0.30** 0.15 
TC (mmol/L) -0.10 -0.15 0.12 0.04 
TG (mmol/L) -0.22 -0.23 0.16 0.13 
LDL-C (mmol/L) -0.13 -0.15 0.16 0.17 
HDL-C (mmol/L) 0.16 0.17 -0.11 -0.36* 
  
Note: Significance of correlation coefficients shown at *p≤ 0.05, **p ≤0.01, ***p≤0.001 
(controlled for age and income). 
Abbreviations: C reactive protein (CRP); Body Mass Index (BMI); Waist Circumference (WC); 
Mean Arterial Pressure (MAP); Fasting Glucose (FG); Insulin (IN); Homeostasis Model 
Assessment of Insulin Resistance (HOMA-IR); Total Cholesterol (TC); Triglycerides (TG); 
Low-Density Lipoprotein Cholesterol (LDL-C); High-Density Lipoprotein Cholesterol (HDL-
C).    
Table 3: Metabolic and physical characteristic based on low and high  
a diponectin to CRP ratio (Mean ± S.E.M) 
 
Variables Adiponectin/CRP ratio Adiponectin/CRP ratio 
  WOMEN MEN 
  Low (n= 39) High (n=38) Low (n=17) High (n=17) 
TC (mmol/L) 4.2 ± 0.1 4.0 ± 0.1 4.1 ± 0.2 4.1 ± 0.2 
LDL-C (mmol/L) 2.4 ± 0.1 2.3 ± 0.1 2.4 ± 0.1 2.2 ± 0.2 
TG (mmol/L) 1.1 ± 0.1 1.0 ± 0.1 1.4 ± 0.1 1.0 ± 0.1 
HDL-C (mmol/L) 1.3 ± 0.1 1.3 ± 0.1 1.1 ± 0.1* 1.3 ± 0.1 
FG (mmol/L) 6.4 ± 0.1** 6.0 ± 0.2 7.0 ± 0.5 6.2 ± 0.5 
IN (µU/mL) 10.0 ± 1.0** 5.0 ± 1.0 
  
HOMA-IR 3.0 ± 0.3** 1.4 ± 0.3           3.0 ± 0.7           1.4 ± 0.7 
WC (cm) 104.1 ± 2.6** 92.1 ± 3.0          104.1 ± 3.7           94.1 ± 4.0 
BF (%) 44.0 ± 1.2** 39.0 ± 1.3          30.0 ± 1.3*           25.2 ± 1.3 
BMI (kg/m2) 34.4 ± 1.1*** 30.1 ± 1.1         31.2 ± 1.2*           27.3 ± 1.1 
MAP (mm Hg) 99 ± 2.0 97 ± 2.3        101 ± 3.3           102 ± 3.3 
 
Note: Mean Differences significant at *p≤ 0.05, **p ≤0.01, ***p≤0.001; (controlled for age and 
income; participants who were in the lower 50 percentile of adiponectin to CRP ratio were 
classified as “low”, participants in the upper 50 percentile were classified as “high”). 
 
Abbreviations: Total Cholesterol (TC); Low-Density Lipoprotein Cholesterol (LDL-C); 
Triglycerides (TG); High-Density Lipoprotein Cholesterol (HDL-C); Fasting Glucose (FG); 
Insulin (IN); Homeostasis Model Assessment of Insulin Resistance (HOMA- IR); Waist 
Circumference (WC); Body Mass Index (BMI); Mean Arterial Pressure (MAP). 
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cantly different between the  two ratio groups.
Figure 1 presents mean plasma adiponectin, CRP and 
adiponectin to CRP ratio by the three metabolic group-
ings and gender. Women with normal FG/%BF had sig-
nificantly higher adiponectin (64±6.0 ng/mL) and lower 
CRP (1.3±0.6 mg/L) concentrations than women with 
normal FG and high %BF (adiponectin: 37.0 ±5.0 ng/
mL and CRP: 3.1±0.5 mg/L) and high FG (adiponectin: 
15.1 ± 4.1 ng/mL and CRP: 4.0 ± 0.5mg/mL). Addition-
ally, adiponectin to CRP ratio differed significantly in all 
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Figure 1: Plasma adiponectin, CRP, and the adiponectin to CRP ratio based on normal %body fat and fast-
ing glucose (Women = 23; Men = 16), high %body fat and normal fasting glucose (Women = 30; Men = 12) 
and normal/high % body fat/high fasting glucose (Women = 43; Men = 21) (Mean ± S.E.M)
Note: Means with different superscript letters differ significantly; p≤ 0.05 (controlled for age and income; ratio of  adiponectin 
to CRP values were multiplied by 1000 to generate whole numbers). Abbreviations: CRP: C-Reactive Protein).
AA men. 
Discussion
Excessive body fat is a major risk for cardiovascular dis-
ease and increases the risk of  hypertension, dyslipidemia, 
hyperglycemia and low-grade inflammation process. Two 
proteins that are associated with T2D and obesity are ad-
iponectin and CRP. Adiponectin is exclusively produced 
by adipocytes, circulates in plasma, and is reduced in obe-
sity, IR, MS and T2D. Adiponectin helps to regulate the 
release of  various inflammatory and anti-inflammatory 
cytokines13,31. Whereas CRP released from the liver in re-
sponse to the inflammatory cytokines - IL-1 beta, IL-6 
and TNF-alpha is a risk factor for cardiovascular events 
and is related to an increased risk of  incident T2D. Al-
though CRP and adiponectin were negatively related, re-
sults from the present study strongly suggests that AA 
women with low adiponectin and high CRP are likely 
to have excessive body fat and glucose dysregulation as 
compared to AA women with high adiponectin and low 
CRP values. In contrast, women who are obese, but not 
pre-diabetic, are likely to have moderately high adiponec-
tin and CRP values. A predictive cut-off  for adiponectin 
could be developed, but an adiponectin/CRP ratio may 
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preclude the need for such a cut-off. 
Previous studies have shown that circulating CRP is a pre-
dictor of  CVD32 whereas adiponectin levels are reflective 
of  IR, central obesity and intra-abdominal fat accumula-
tion16,33,34. In the present study, adiponectin was negatively 
correlated with many markers (BMI, WC, %BF, and FG), 
whereas CRP was positively correlated with various met-
abolic markers (BMI, WC, %BF, IN, FG and HOMA-IR) 
in AA women. Although CRP and adiponectin were neg-
atively related, the strength of  the relationship was low; 
combining the two variables may provide more valuable 
information regarding obesity and diabetes than any of  
the individual variables. Interestingly, the observed trends 
were not seen in AA men.
Adiponectin and CRP are independent risk factors of  
CVD, together serve a synergistic role in metabolic reg-
ulation in the general population and T2D subjects35-37. 
We found that AA women with high adiponectin and low 
CRP levels, which translated into a high ratio, had signifi-
cantly lower FG, IN, HOMA-IR, WC, %BF and BMI rel-
ative to those with a low ratio. A combined measurement 
of  these markers may be more useful for detecting per-
sons at high risk for cardiovascular disease and diabetes, 
than one of  the measure alone.
Although obesity is a risk factor for insulin resistance, 
CVD and T2DM, not every obese individual suffers the 
same metabolic dysregulation. In the 1980s, a subgroup 
of  metabolically normal, but obese, individuals with rel-
atively high insulin sensitivity and a favorable metabolic 
profile was reported by several investigators38. A unique 
subset of  obese individuals appears to be protected from 
developing the metabolic disturbances typically associat-
ed with obesity. These individuals, despite being obese 
display normal to high insulin sensitivity and favorable 
cardiovascular risk profiles39-43. Thus, it is important to 
characterize differences between these groups to uncov-
er additional mechanisms connecting obesity and health 
risk. In our study, we examined differences in adiponectin 
and CRP and the adiponectin to CRP ratio in AA men 
and women with normal %BF/FG, high %BF/normal 
FG and normal and high %BF with high FG. Whereas 
no differences were noted between the men by metabolic 
group assignment, plasma adiponectin was consistently 
lower and CRP higher in women in the high FG group 
compared to women in the normal %BF/FG and in the 
high %BF/normal FG group. The high FG also had a 
significantly lower adiponectin to CRP ratio relative to the 
other metabolic groups of  women. Our findings are also 
consistent with epidemiological studies showing that cir-
culating levels of  adiponectin are lower in diabetic than in 
healthy individuals44,45. Additionally, studies have report-
ed that heavier individuals had greater health benefit and 
lower health risks from high levels of  adiponectin than 
their lean counterparts46,47. Whether a combined measure 
of  these two markers, such as adiponectin/CRP ratio, 
would be useful for detecting and monitoring metabolic 
and low-grade inflammation health risk in AA women re-
mains to be fully understood.
Gender differences in adiponectin and CRP levels have 
previously been reported23,48,49, and our study provides 
further evidence of  these gender differences because AA 
women had significantly higher adiponectin and CRP 
levels than AA men. Additionally, we found a significant 
negative association between plasma adiponectin and 
CRP in both genders. 
Limitations 
We had data on fewer men than women, and this may 
have limited our findings among men. The present study 
examined only AA and it would be interesting to exam-
ine differences across other ethnic overweight/obese and 
diabetic/ non diabetic groups by gender as well. Longitu-
dinal research with more participants will be necessary to 
determine the independent and interactive relationships 
between adiponectin and hs-CRP, and the health out-
comes they reflect. 
Conclusion
A statistically significant negative association was ob-
served between plasma adiponectin and CRP in both AA 
men and women; AA women had higher adiponectin and 
CRP levels compared to AA men. Overall, AA women 
with high fasting glucose and HOMA -IR had lower con-
centrations of  adiponectin and higher CRP levels than 
AA women with normal glucose. Measures of  obesity and 
metabolic dysregulation are more strongly related to CRP 
and adiponectin in AA women than in AA men. Finally, 
the ratio of  circulating levels of  adiponectin to CRP was 
examined and found to discriminate between AA women 
who were diabetic versus those who were not, regardless 
of  obesity status, which suggests that adiponectin may 
have a protective effect against obesity related metabolic 
derangements in AA women. Prospective studies will be 
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needed to confirm this finding.
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